Flonase Ad Claims Settlement Confidential, But McNeil Likely Gains Choosing Court Over NAD
This article was originally published in The Tan Sheet
Executive Summary
When prompt action is a primary goal, as McNeil aimed for in challenging ad claims for Glaxo’s Flonase Allergy Relief, lawyers say going to court is a better option than going to the National Advertising Division. Even with allegations that wither under the opposing firm’s rebuttal, litigation of advertising complaints it gains publicity than a NAD review would generate.
You may also be interested in...
NAD Has ‘High Hopes’ Firms Will Cooperate On Schedules To Accelerate Reviews
The National Advertising Division changes its review process to allow opposing companies greater control over scheduling and resolving their disputes. The changes, recommended by ABA committees, also impose fees on both firms in appeals and allow more time for compliance with decisions.
NAD Has ‘High Hopes’ Firms Cooperate On Schedules To Accelerate Reviews
The National Advertising Division changes its review process to allow opposing firms some control over scheduling in the process and in resolving their disputes. The changes, recommended by ABA committees, also impose fees for both firms in appeals and allow more time for compliance with decisions.
NAD Has ‘High Hopes’ Firms Cooperate On Schedules To Accelerate Reviews
The National Advertising Division changes its review process to allow opposing firms some control over scheduling in the process and in resolving their disputes. The changes, recommended by ABA committees, also impose fees for both firms in appeals and allow more time for compliance with decisions.